Key Highlights

  • Exicure (NASDAQ:XCUR) rose 10.09% to USD 1.20 in the pre-market snapshot of Tuesday, October 27, 2026 with no dated announcement. Nasdaq extended its minimum stockholders' equity compliance deadline to Wednesday, December 2, 2026, and cash was USD 3.7 million at the end of 2025.
  • Onconetix (NASDAQ:ONCO) fell 13.43% to USD 0.3455 after announcing a 1-for-10 reverse stock split, expected on Friday, November 6, 2026, with revenue of USD 17,120 and cash of about USD 5.9 million at June 30, 2026.
  • RedCloud Holdings (NASDAQ:RCT) fell 11.00% to USD 0.0736 after repaying its convertible notes. Nasdaq issued a delisting determination over the USD 1.00 minimum bid price, and a 20-for-1 consolidation goes to a shareholder vote on Friday, October 30, 2026.
  • Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) fell 7.31% to USD 2.03, one session after a 1-for-20 reverse split took effect, while fiscal year 2026 revenue was USD 13.43 million, down 33.87%.

Exicure (NASDAQ:XCUR): an equity rule that a split cannot fix

Exicure (NASDAQ:XCUR), a clinical-stage biotechnology company developing burixafor, a drug candidate under study for stem cell mobilisation before transplant, traded at USD 1.20, up 10.09%. Simple arithmetic on the snapshot implies a prior close of about USD 1.09. No company-specific announcement dated on or just before the session accompanied the move. The latest release identified, of Wednesday, September 16, 2026, reported the Nasdaq extension, so the gain appears consistent with thin pre-market liquidity and speculative trading in a small capitalisation stock.

Exicure faces a minimum stockholders' equity rule of USD 2.5 million, against reported equity of about USD 2.1 million at Tuesday, March 31, 2026, so a higher quoted price does not help. In its release of Wednesday, March 25, 2026, the net loss narrowed to USD 4.9 million from USD 9.7 million, aided by a USD 6.0 million non-operating gain from an early lease termination. Management stated that liquidity may be insufficient for the next 12 months. The bear reading is delisting if the rule is not met, or dilution to repair equity. The bull reading rests on Phase 2 mobilisation data, with 89.5% to 89.7% of patients meeting the primary endpoint.

Onconetix (NASDAQ:ONCO): a split announced at a going concern company

Onconetix (NASDAQ:ONCO), a commercial-stage oncology company that owns the Swiss prostate cancer diagnostics business Proteomedix, traded at USD 0.3455 in the pre-market snapshot. The company's release of Monday, October 26, 2026 announced board approval of a 1-for-10 reverse stock split, expected to take effect on Friday, November 6, 2026. The split would cut common shares from about 5,886,774 to about 588,677, with cash paid in place of fractional shares. A reverse split consolidates shares to raise the quoted price without changing the value of each holder's stake. The decline appears consistent with the usual market reaction, which is an inference.

The Form 10-Q for the quarter ended June 30, 2026 reported a net loss of USD 2,867,303, or USD 1.28 per share, and states substantial doubt about continuing as a going concern. Cash was about USD 5.4 million at Monday, August 10, 2026. A share exchange agreement to acquire Realbotix LLC for stock requires shareholder and regulatory approvals, and Realbotix Corp reported third quarter revenue of USD 354,000, against USD 595,000 a year earlier. The bear reading adds a repeated consolidation, since dilution through preferred stock remains possible, and a bridge facility that accrues interest of 12% a year if the agreement terminates.

RedCloud Holdings (NASDAQ:RCT): a delisting determination under appeal

RedCloud Holdings (NASDAQ:RCT), a United Kingdom-based operator of a business-to-business digital trading platform for fast-moving consumer goods in emerging markets, traded at USD 0.0736 in the pre-market snapshot. The company's release of Monday, October 26, 2026 stated that the senior convertible notes issued in February 2026 were repaid in full using a non-dilutive shareholder loan. The terms of that loan were not stated. The decline after a debt reduction appears consistent with the open listing uncertainty and thin liquidity, which is an inference.

Nasdaq issued a delisting determination received on Tuesday, October 13, 2026 over the USD 1.00 minimum bid price. The company requested a hearing, which stays any suspension or delisting pending a panel decision, and a separate deficiency concerns the USD 35,000,000 minimum market value requirement. Six-month revenue to June 30, 2026 was USD 24.0 million, up 34%, with a net loss of USD 18.5 million, narrowed by 30%, and operating cash outflow fell to USD 8,207,239 from USD 15,916,911. The consolidation is expected on about Friday, November 13, 2026 if shareholders approve, and a share priced below USD 0.10 trades with wide spreads.

Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD): the split is done, the test is holding

Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD), an investment holding company that distributes over-the-counter pharmaceuticals and health supplements across Hong Kong and Mainland China, traded at USD 2.03 in the pre-market snapshot. That follows a close of USD 2.19 on Monday, October 26, 2026, up 9.50% in the first session after the 1-for-20 split announced on Wednesday, October 21, 2026. The decline appears consistent with a partial give-back of that first-day gain, a pattern that often follows reverse splits in low-priced shares.

The split raised the par value from USD 0.001 to USD 0.02 per share and rounded fractional shares up. It followed a deficiency notice of Friday, January 16, 2026 and a grace period granted on Thursday, July 16, 2026. A closing bid of at least USD 1.00 for ten consecutive business days would normally satisfy the rule, leaving a margin of more than 100%. Revenue fell to USD 13.43 million from USD 20.31 million, according to market data derived from the annual report on Form 20-F, and a USD 200 million mixed securities shelf registration would allow future share issuance.

Where Things Stand

The answer is that Nasdaq rules move these shares because each name sits at a different point in the process. Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) has completed its split and is testing the new price. Onconetix (NASDAQ:ONCO) has only announced one, while RedCloud Holdings (NASDAQ:RCT) is appealing a determination before its own consolidation. Exicure (NASDAQ:XCUR) faces an equity test that no split can cure.

The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, which follows the rate rise to 4.00% from 3.75% on Wednesday, September 16, 2026, the RedCloud shareholder vote on Friday, October 30, 2026, the Onconetix split on Friday, November 6, 2026 and the Exicure deadline of Wednesday, December 2, 2026. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.